All articles by Nikitha Ladda
Nikitha Ladda
UK doctors fear job losses as government reshuffles healthcare spending
Patients in the UK could lose as many as 2,400 doctors under the government’s Comprehensive Spending Review, the Royal College of General Practitioners (RCGP) has warned.
Two HIV-positive patients cleared of virus after bone marrow transplants
Two HIV-positive patients have been taken off their anti-retroviral drugs after bone marrow transplants seemed to clear the virus from their bodies, researchers announced at the International Aids Society Conference.
FDA awards Activartis brain cancer drug Orphan Drug Designation
Austrian biotech company Activartis has received Orphan Drug Designation for its cancer immunotherapy AV0113 from the US Food and Drug Administration.
Global raid seizes fake drugs worth $40.8m
Counterfeit and unlicensed drugs valued at $40.8m have been seized by the International Criminal Police Organization (Interpol) in a week-long global crackdown on the illegal internet medicines trade.
Sanofi’s Lyxumia approved to treat diabetes in Japan
French drug maker Sanofi has announced that its injectable diabetes treatment Lyxumia has been approved in Japan.
Roche, AstraZeneca to share drug research data
Roche and AstraZeneca have launched a consortium that will share early research data related to drug design to accelerate the discovery of new compounds.
Medicines Australia to expose drug company handouts to doctors
Healthcare professionals in Australia who accept payments from drug companies will be named and shamed on a public register, the Transparency Working Group has announced.
Tenofovir cuts HIV infection rates by half in drug users
The first clinical trial to assess whether antiretrovirals can reduce HIV transmission in injecting drug users has shown that tenofovir slashed HIV infection rates by almost half, compared with a placebo.
Women in UK to be offered preventative breast cancer drugs
Hundreds of thousands of women in England and Wales with a family history of breast cancer could be given drugs to prevent the disease.
Astellas Pharma bags European approval for prostate cancer drug
The European Commission has granted marketing authorisation for Xtandi, an oral prostate cancer drug developed by Astellas Pharma and US-based Medivation.